Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
62 (26%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-KETOROLAC INJECTABLE | 30MG | SOLUTION | Actual shortage | 2017-08-16 | 2017-10-05 | 19595 |
| APO-KETOTIFEN - SYR 1MG/5ML | 1MG | SYRUP | Actual shortage | 2017-08-13 | 2017-10-05 | 19024 |
| APO-LABETALOL | 200MG | TABLET | Resolved | 2024-06-20 | 2024-06-28 | 231030 |
| APO-LABETALOL | 100MG | TABLET | Resolved | 2024-09-27 | 2024-10-25 | 238826 |
| APO-LABETALOL | 200MG | TABLET | Resolved | 2024-09-27 | 2024-11-29 | 238829 |
| APO-LABETALOL | 200MG | TABLET | Resolved | 2023-02-23 | 2023-03-02 | 185489 |
| APO-LABETALOL | 100MG | TABLET | Resolved | 2023-06-16 | 2023-07-21 | 195069 |
| APO-LABETALOL | 200MG | TABLET | Resolved | 2023-07-13 | 2023-07-21 | 198511 |
| APO-LABETALOL | 200MG | TABLET | Resolved | 2023-11-10 | 2024-01-05 | 209964 |
| APO-LABETALOL | 100MG | TABLET | Resolved | 2023-12-01 | 2024-01-05 | 212359 |
| APO-LABETALOL | 100MG | TABLET | Resolved | 2022-09-30 | 2022-10-14 | 170804 |
| APO-LABETALOL | 100MG | TABLET | Resolved | 2017-08-13 | 2021-01-11 | 19105 |
| APO-LABETALOL | 200MG | TABLET | Resolved | 2017-08-13 | 2021-01-11 | 19108 |
| APO-LAMIVUDINE | 300MG | TABLET | Resolved | 2017-07-11 | 2017-08-31 | 15271 |
| APO-LAMIVUDINE | 300MG | TABLET | Resolved | 2021-02-26 | 2021-06-28 | 134757 |
| APO-LAMIVUDINE | 150MG | TABLET | Resolved | 2017-03-11 | 2017-05-16 | 664 |
| APO-LAMIVUDINE HBV | 100MG | TABLET | Resolved | 2021-05-07 | 2021-06-28 | 138957 |
| APO-LAMIVUDINE HBV | 100MG | TABLET | Resolved | 2019-12-05 | 2020-02-25 | 100278 |
| APO-LAMIVUDINE-ZIDOVUDINE | 300MG 150MG | TABLET | Resolved | 2017-12-06 | 2018-07-03 | 31907 |
| APO-LAMIVUDINE-ZIDOVUDINE | 300MG 150MG | TABLET | Resolved | 2023-01-13 | 2023-01-20 | 181110 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-LAMIVUDINE | 300MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60560 |
| APO-LAMIVUDINE HBV | 100MG | TABLET | Discontinued | 2018-09-07 | 2019-12-21 | 60563 |
| APO-LATANOPROST-TIMOP | Discontinued | 2018-09-07 | 2018-09-15 | 60572 | ||
| APO-LEVOCARB | 25MG 250MG | TABLET | Discontinued | 2018-09-07 | 2019-02-07 | 60576 |
| APO-LISINOPRIL | 10MG | TABLET | Discontinued | 2018-09-07 | 2019-02-02 | 60579 |
| APO-LISINOPRIL | 20MG | TABLET | Discontinued | 2018-09-07 | 2018-11-26 | 60582 |
| APO-LISINOPRIL | 5MG | TABLET | Discontinued | 2018-09-07 | 2019-02-13 | 60585 |
| APO-LISINOPRIL/HCTZ | 12.5MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1090 |
| APO-LISINOPRIL/HCTZ | 12.5MG 10MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1093 |
| APO-LISINOPRIL/HCTZ | 25MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1096 |
| APO-LITHIUM CARBONATE | 300MG | CAPSULE | Discontinued | 2018-09-07 | 2018-09-15 | 60588 |
| APO-LOPERAMIDE | 2MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4930 |
| APO-LORAZEPAM | 0.5MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60591 |
| APO-LORAZEPAM | 1MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60594 |
| APO-LOSARTAN | 25MG | TABLET | Discontinued | 2019-02-01 | 2019-02-02 | 74376 |
| APO-LOSARTAN | 50MG | TABLET | Discontinued | 2018-09-10 | 2018-09-15 | 60987 |
| APO-LOSARTAN | 100MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71213 |
| APO-LOSARTAN/HCTZ | 12.5MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-11-02 | 60597 |
| APO-LOSARTAN/HCTZ | 25MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60600 |
| APO-LOSARTAN/HCTZ | 12.5MG 50MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60603 |